The Achillion team has the talent and commitment to solve challenging problems in drug development
Achillion applies expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving patients’ lives. The company’s scientific excellence, integrated capabilities and experienced team position it to successfully advance new products along the entire continuum from the bench to the patient.
Achillion is advancing a second-generation NS5A inhibitor, ACH-3102, a potent inhibitor of HCV NS5A that demonstrates pico-molar potency, pan-genotypic activity, and an enhanced resistance profile compared to first-generation NS5A inhibitors. Achillion is also advancing once-daily NS3/4A protease inhibitors including ACH-2684, a potent, second-generation compound entering Phase 2, and sovaprevir, an investigational Phase 2 protease inhibitor. Lastly, Achillion has discovered a novel nucleotide NS5B polymerase inhibitor, ACH-3422.
Furthermore, Achillion has advanced a novel platform for the advancement of small molecule complement factor D inhibitors for the treatment of complement-related diseases. Each of these programs was discovered through Achillion's own proprietary internal drug discovery efforts.
Achillion is headquartered in New Haven, Connecticut. Achillion's common stock trades on the NASDAQ Global Select Market under the symbol: ACHN.